Separation and determination method for related impurities of bemetimolol eye drops
Through HPLC method and gradient elution technology, the problem of impurity separation and determination in bemelstimolol eye drops was solved, and efficient and accurate impurity separation and determination were achieved, meeting the standards of drug quality control, especially in In the absence of relevant standards, important quality analysis methods are provided.
Patent Information
- Application Number
- CN202310650416.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-03
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-06-03
AI Technical Summary
The existing technology has failed to effectively solve the problem of separation and determination of impurities in bemelstimolol eye drops, resulting in increased difficulty in quality control, especially in the United States Pharmacopoeia, Japan Pharmacopoeia and the National Drug Administration’s imported drug registration standards. Related standards.
Using high performance liquid chromatography (HPLC) method, the test sample solution, control solution, system suitability solution and blank auxiliary material solution were prepared, combined with gradient elution technology, and octane was used as the stationary phase and octane. Sodium sulfonate buffer was used as mobile phase to separate and determine the impurities in bemesiloxolol eye drops.
It has achieved effective separation and determination of impurities related to bemestimolol eye drops, which has strong specificity, high sensitivity, good repeatability, simple operation, stable and reliable results, and meet the requirements of drug quality control.
Smart Images

Figure CN119064515A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of high performance liquid chromatography analysis, and in particular to a method for separating and determining impurities related to bemisol timolol eye drops. Background Art
[0002] Bimatoprost Timolol Eye Drops is a compound preparation of bimatoprost and timolol. Bimatoprost is a synthetic prostaglandin, a structural analog of prostaglandins with intraocular pressure-lowering activity. Bimatoprost selectively mimics the effects of prostaglandins, and reduces intraocular pressure (IOP) by increasing the outflow of aqueous humor through the trabecular meshwork and the sclerae. Timolol is a non-selective β-adrenergic receptor blocker that has an IOP-lowering effect on both patients with high intraocular pressure and normal people. The exact mechanism of timolol's IOP-lowering effect is still unclear, and intraocular pressure tracing and aqueous humor fluorescence studies suggest that its IOP-lowering effect is related to reduced aqueous humor production. Timolol has no obvious endogenous sympathomimetic activity and local anesthetic effect, and has no direct inhibitory effect on the myocardium.
[0003] Generally speaking, compound drugs introduce many types of impurities, and the properties of the impurities vary greatly, so the introduced impurities need to be controlled. At present, the quality standards of Bemisol Timolol Eye Drops are not included in the United States Pharmacopoeia, the Japanese Pharmacopoeia, and the National Drug Administration's imported drug registration standards. In view of this, it is of great significance to develop a highly specific, efficient and accurate analytical method for quality analysis of Bemisol Timolol Eye Drops. Summary of the invention
[0004] In order to achieve accurate analysis and control of the impurity content in Bemisol Timolol Eye Drops, the present application provides a method for separating and determining impurities related to Bemisol Timolol Eye Drops.
[0005] A method for separating and determining impurities related to Bimeisu Timolol Eye Drops, using HPLC method, comprises the following steps: Prepare the test solution: dissolve and dilute the test sample in water; Prepare control solution: dissolve and dilute timolol maleate in water; Prepare system suitability solution: Take Bimetin Timolol Eye Drops and its related impurities, mix and dilute with water; Prepare blank auxiliary material solution: take sodium chloride, disodium hydrogen phosphate heptahydrate, citric acid, benzalkonium chloride and bimatoprost, dissolve and dilute with water; Determination of retention time: blank excipient solution and system suitability solution were sampled and analyzed to determine the retention time of the impurities related to Bimeisu Timolol Eye Drops; Target substance separation and detection: Take the test solution and the control solution for sampling and detection, and calculate the content of relevant impurities in the test solution according to the main component external standard method; The HPLC uses octadecylsilane bonded silica gel as the stationary phase, sodium octane sulfonate buffer as the mobile phase A, and methanol as the mobile phase B for gradient elution.
[0006] The main components of the bemaprost timolol eye drops of the present application are bemaprost and timolol maleate, and the molecular structure thereof is shown below. Based on this, the reference substance used in the analysis method of the present application is timolol maleate, which is conducive to improving the reliability and accuracy of the analysis results.
[0007] Bimatoprost Timolol Maleate Preferably, the relevant impurities include: Impurity B: 3-(tert-butylamino)-2-((4-morpholin-1,2,5-thiadiazol-3-yl)oxy)-1-propanol maleate; Impurity C: N-(tert-butyl)-2,3-bis((4-morpholin-1,2,5-thiadiazol-3-yl)oxy)-1-propylamine maleate; Impurity D: 4-morpholino-1,2,5-thiadiazol-3-ol; Impurity E: (S,Z)-4-((1-(tert-butylamino)-3-((4-morpholin-1,2,5-thiadiazol-3-yl)oxy)prop-2-yl)oxy)-4-oxobut-2-enoic acid; Impurity F: 4-(4-chloro-1,2,5-thiadiazol-3-yl)morpholine; Impurity G: 4-morpholin-1,2,5-thiadiazol-3(2H)-one 1-oxide; Impurity H: 2-(3-(tert-butylamino)-2-hydroxypropyl)-4-morpholin-1,2,5-thiadiazol-3(2H)-one; Impurity I: 1-(ethylamino)-3-((4-morpholin-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; Impurity J: 3,3'-((1,2,5-thiadiazole-3,4-diyl)bis(oxy))bis(1-(tert-butylamino)propanol).
[0008] Preferably, the gradient elution is set as follows: 0~20min: 45~50%A→27~33%A; 20~30min: 27~33%A→27~33%A; 30~31min: 27~33%A→45~50%A; 31~40min: 45~50%A→45~50%A.
[0009] Preferably, the gradient elution is set as follows: 0~20min: 48%A→30%A; 20~30min: 30%A→30%A; 30~31min: 30%A→48%A; 31~40min: 48%A→48%A.
[0010] Preferably, the flow rate of the gradient elution is 0.9-1.1 ml / min, more preferably 1.0 ml / min.
[0011] Preferably, the content of timolol in the test solution is 1 mg / ml.
[0012] Preferably, the timolol content in the control solution is 2 μg / ml.
[0013] Preferably, the pH value of the sodium octane sulfonate buffer is 2.8 to 3.2; more preferably 3.0.
[0014] Preferably, the concentration of sodium octane sulfonate salt in the sodium octane sulfonate buffer is 4.3-4.34 g / L; more preferably 4.32 g / L.
[0015] Preferably, the sodium octane sulfonate buffer is obtained by adding glacial acetic acid to an aqueous solution of sodium octane sulfonate.
[0016] Preferably, the filler particles of the octadecylsilane bonded silica gel have a particle size of 2 to 5 μm; and the column temperature of the chromatographic column used in the HPLC is 33 to 37°C.
[0017] Preferably, the detection wavelength of the detector used in the HPLC is 295±2 nm.
[0018] In summary, this application has the following beneficial effects: The method of the present invention can effectively separate the relevant impurities of Bimeisu Timolol Eye Drops and determine the content thereof, and the method has the advantages of strong specificity, high sensitivity, high efficiency and accuracy, good repeatability and durability, simple operation, stable and reliable results, etc. It is of great significance for achieving the quality control of Bimeisu Timolol Eye Drops. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 It is a solution chromatogram of system suitability under the conditions of Example 1 of the present application.
[0020] Figure 2 System suitability solution chromatogram under the conditions of Control Example 1.
[0021] Figure 3 System suitability solution chromatogram under the conditions of Control Example 2.
[0022] Figure 4 System suitability solution chromatogram under the conditions of Control Example 3. DETAILED DESCRIPTION
[0023] The preferred embodiments of the present invention will be described in detail below with reference to the accompanying drawings. The experimental methods without specific conditions in the preferred embodiments are usually carried out under conventional conditions. The examples are provided to better illustrate the contents of the present invention, but the contents of the present invention are not limited to the examples. Therefore, those skilled in the art can make non-essential improvements and adjustments to the implementation scheme according to the above invention content, which still fall within the protection scope of the present invention. Example
[0024] Example 1, separation and determination method of impurities related to Bimeisu Timolol Eye Drops: 1. Chromatographic conditions Chromatographic column: Kromasil 100-5C18, 250mm×4.6mm, 5μm, mobile phase A: 4.32g / L sodium octane sulfonate solution (take 4.32g of sodium octane sulfonate, add 1000ml of water to dissolve, and adjust the pH value to 3.0 with glacial acetic acid), mobile phase B: methanol, gradient elution, the gradient elution settings are as follows: Flow rate: 1 ml / min, column temperature: 35°C, detection wavelength: 295 nm, injection volume: 20 μl.
[0025] 2. Methods and Results 2.1 Solution preparation Test solution: dilute the test sample with water to make a solution containing 1 mg of timolol per 1 ml of water; Reference solution: Take an appropriate amount of timolol maleate reference substance, weigh accurately, dissolve in water and quantitatively dilute to make a solution containing about 2 μg of timolol per 1 ml; System suitability solution (spiked test solution): Take Bimetin timolol eye drops and impurities B, C, D, E, F, G, H, I and J, dissolve and dilute with water to prepare a solution containing 1 mg of timolol and 2 μg of each impurity per 1 ml of water; Blank excipient solution: Take appropriate amounts of sodium chloride, disodium hydrogen phosphate heptahydrate, citric acid, benzalkonium chloride and bimatoprost, weigh accurately, add water to dissolve and dilute to make a solution containing approximately 6.8 mg of sodium chloride, 2.68 mg of disodium hydrogen phosphate heptahydrate, 0.14 mg of citric acid, 0.05 mg of benzalkonium chloride and 0.3 mg of bimatoprost per 1 ml. Accurately transfer 1 ml of the above solution into a 5 ml volumetric flask and dilute to the scale with water.
[0026] 2.2 Exclusivity Accurately measure the above blank excipient solution and system suitability solution for injection and record the chromatogram.
[0027] Blank excipient solution has no interference with any impurities; Figure 1 As shown in the figure, in the system suitability solution, the order of peaks is maleic acid retention time Rt of 1.9min, impurity G (retention time Rt 2.841min), impurity D (retention time Rt5.615min), impurity E (retention time Rt 8.120min), impurity H (retention time Rt 10.102min), impurity B (retention time Rt 11.321min), impurity I (retention time Rt 12.774min), impurity F (retention time Rt 13.806min), timolol retention time Rt of 14.439min, impurity J (retention time Rt 19.576min), impurity C (retention time Rt24.170min); the separation degree of each impurity and timolol is greater than 1.5.
[0028] 2.3 Repeatability Accurately measure the control solution and the spiked test solution and inject them, and record the chromatogram. Calculate the RSD of the content of each related substance in the 6 spiked test solutions by the main component external standard method with correction factor. The RSD of the content of each related impurity detected in the 6 spiked test solutions is less than 10.0%, which meets the requirements of high performance liquid chromatography for the detection of related substances.
[0029] 2.4 Intermediate precision The intermediate precision test was conducted by different analysts, on different dates, and with different instruments using the same method. The RSD of the contents of the relevant impurities detected in the 12 spiked test solutions was less than 10.0%, which met the requirements for the detection of relevant substances by HPLC.
[0030] 2.4 Linearity Take Bimeisu Timolol Eye Drops and its impurities B, C, D, E, F, G, H, I, and J, dissolve in water and dilute to make a mixed solution containing 10 μg of each of Timolol, B, C, D, E, F, G, H, I, and J in 1 ml as a linear stock solution. Accurately pipette 2.5 ml of the linear stock solution into 50 ml, 2.5 ml into 25 ml, 7.5 ml into 50 ml, 2 ml into 10 ml, 4 ml into 10 ml, and 6 ml into 10 ml volumetric bottles, dilute with water to the scale, and use it as a linear series solution. Take the quantitative limit solution as the linear minimum point. Linear regression is performed on the concentration using the peak area to obtain a linear equation (see Table 1). Timolol and related impurities have a good linear relationship within the linear range.
[0031] Table 1. Linearity test results 2.5 Limit of detection and limit of quantification A series of solutions (see Table 2) were prepared by taking appropriate amounts of timolol and various impurity reference substances. When S / N≥10, they were used as quantitative limit solutions, and when S / N≥3, they were used as detection limit solutions. The results are shown in Table 2.
[0032] Table 2. Results of limit of quantification and limit of detection 2.6 Accuracy Take Bemiso Timolol Eye Drops and impurities B, C, D, E, F, G, H, I, J, dissolve and dilute with water to make a solution containing 1 mg of timolol and 1 μg of each impurity in 1 ml, as a 50% recovery solution; take Bemiso Timolol Eye Drops and its impurities B, C, D, E, F, G, H, I, J, dissolve and dilute with water to make a solution containing 1 mg of timolol and 2 μg of each impurity in 1 ml, as a 100% recovery solution; take Bemiso Timolol Eye Drops and its impurities B, C, D, E, F, G, H, I, J, dissolve and dilute with water to make a solution containing 1 mg of timolol and 3 μg of each impurity in 1 ml, as a 150% recovery solution; each concentration is parallel 3 times. Take the recovery solution and the control solution, inject and analyze, and record the chromatogram. The recovery rate and RSD of each impurity were calculated by the main component external standard method with correction factor. The results showed that the recovery rate of each impurity at each concentration was between 80.0% and 120.0%, and the RSD was less than 10.0%, which met the requirements of high performance liquid chromatography for the detection of related substances. The results are shown in Table 3.
[0033] Table 3. Accuracy results 3. Conclusion Under the chromatographic conditions, Bemisol Timolol Eye Drops and its related impurities can be completely separated. This method has strong specificity and high sensitivity. The accuracy, repeatability and intermediate precision all meet the technical requirements of drug quality research standards, and the results obtained are stable and reliable.
[0034] Comparison Example Comparative Example 1 1. Chromatographic conditions Chromatographic column: Waters Symmetry C18 (3.9 mm × 150 mm, 5 μm), mobile phase A: 4.32 g / L sodium octyl sulfonate buffer (pH 3.0)-methanol (50:50), mobile phase B: methanol, gradient elution, gradient elution settings are as follows: Flow rate: 1.2 ml / min, column temperature: 35°C, detection wavelength: 295 nm, injection volume: 20 μl.
[0035] 2. Methods Take Bimeisu Timolol Eye Drops and impurities B, C, D, E, F, G, H, I and J, dissolve and dilute with water to make a solution containing 1 mg of Timolol and 2 μg of related impurities per 1 ml, as the system suitability solution. Accurately measure 20 μl and inject it into the liquid chromatograph, record the chromatogram, and the system suitability solution chromatogram is attached. Figure 2 .
[0036] 3. Conclusion: Under the chromatographic conditions, impurity F and impurity I overlap (Rt 5.8min), impurity G (Rt 1.0min) peaks at the front and does not achieve baseline separation with the maleic acid peak (Rt 0.7min).
[0037] Comparative Example 2 1Chromatographic conditions: Chromatographic column: ACE Excel 1.7C18-PFP (2.1 mm × 100 mm, 1.7 μm), mobile phase A: trifluoroacetic acid-water (0.5:1000), mobile phase B: trifluoroacetic acid-acetonitrile (0.5:1000), gradient elution, gradient elution settings are as follows: Time (min) A(%) B(%) 0 84 16 2.4 84 16 8 20 80 8.1 84 16 11 84 16 Flow rate: 0.1 ml / min, column temperature: 30°C, detection wavelength: 295 nm, injection volume: 2.5 μl.
[0038] 2. Methods Take Bimeisu Timolol Eye Drops and impurities B, C, D, E, F, G, H, I and J, dissolve and dilute with water to make a solution containing 1 mg of Timolol and 2 μg of related impurities per 1 ml, as the system suitability solution. Accurately measure 20 μl and inject it into the liquid chromatograph, record the chromatogram, and the system suitability solution chromatogram is attached. Figure 3 .
[0039] 3. Conclusion: Under the chromatographic conditions, the impurities were not completely separated.
[0040] Comparative Example 3 1. Chromatographic conditions: Chromatographic column: Waters Xbridge-C18 (4.6 mm × 150 mm, 3.5 μm), mobile phase A: 0.01% phosphate buffer (pH 3.0)-methanol (80:20), mobile phase B: acetonitrile-methanol (70:30), gradient elution, gradient elution settings are as follows: Time (min) A(%) B(%) 0 82 18 5 82 18 5.1 60 40 16 60 40 17 82 18 25 82 18 Flow rate: 1.0 ml / min, column temperature: 30°C, detection wavelength: 295 nm, injection volume: 5 μl.
[0041] 2. Methods: Take Bimeisu Timolol Eye Drops and impurities B, C, D, E, F, G, H, I and J, dissolve and dilute with water to make a solution containing 1 mg of Timolol and 2 μg of each impurity per 1 ml, as the system suitability solution. Accurately measure 5 μl and inject it into the liquid chromatograph, record the chromatogram, and the chromatogram of the system suitability solution is attached. Figure 4 .
[0042] 3 Conclusion: Under this chromatographic condition, the main peak shape is poor.
[0043] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.
Claims
1. A method for separating and determining impurities related to Bimeisu Timolol Eye Drops, characterized in that: The HPLC method comprises the following steps: Prepare the test solution: dissolve and dilute the test sample in water; Prepare the control solution: dissolve and dilute timolol maleate in water; Prepare system suitability solution: Take Bimetin Timolol Eye Drops and its related impurities, mix and dilute with water; Prepare blank auxiliary material solution: take sodium chloride, disodium hydrogen phosphate heptahydrate, citric acid, benzalkonium chloride and bimatoprost, dissolve and dilute with water; Determination of retention time: blank excipient solution and system suitability solution were sampled and analyzed to determine the retention time of impurities related to Bimeisu Timolol Eye Drops; Target substance separation and detection: Take the test solution and the control solution for sampling and detection, and calculate the content of relevant impurities in the test solution according to the main component external standard method; The HPLC uses octadecylsilane bonded silica gel as the stationary phase, sodium octane sulfonate buffer as the mobile phase A, and methanol as the mobile phase B for gradient elution.
2. The method for separating and determining impurities related to the bemisutol timolol eye drops according to claim 1, characterized in that: The relevant impurities include: Impurity B: 3-(tert-butylamino)-2-((4-morpholin-1,2,5-thiadiazol-3-yl)oxy)-1-propanol maleate; Impurity C: N-(tert-butyl)-2,3-bis((4-morpholin-1,2,5-thiadiazol-3-yl)oxy)-1-propylamine maleate; Impurity D: 4-morpholino-1,2,5-thiadiazol-3-ol; Impurity E: (S,Z)-4-((1-(tert-butylamino)-3-((4-morpholin-1,2,5-thiadiazol-3-yl)oxy)prop-2-yl)oxy)-4-oxobut-2-enoic acid; Impurity F: 4-(4-chloro-1,2,5-thiadiazol-3-yl)morpholine; Impurity G: 4-morpholin-1,2,5-thiadiazol-3(2H)-one 1-oxide; Impurity H: 2-(3-(tert-butylamino)-2-hydroxypropyl)-4-morpholin-1,2,5-thiadiazol-3(2H)-one; Impurity I: 1-(ethylamino)-3-((4-morpholin-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; Impurity J: 3,3'-((1,2,5-thiadiazole-3,4-diyl)bis(oxy))bis(1-(tert-butylamino)propanol).
3. The method for separating and determining impurities related to the bemisutol timolol eye drops according to claim 1, characterized in that: The gradient elution was set up as follows: 0~20min: 45~50%A→27~33%A; 20~30min: 27~33%A→27~33%A; 30~31min: 27~33%A→45~50%A; 31~40min: 45~50%A→45~50%A; The flow rate of the gradient elution is 0.9-1.1 ml / min.
4. The method for separating and determining impurities related to the bemisutol timolol eye drops according to claim 1, characterized in that: The gradient elution was set up as follows: 0~20min: 48%A→30%A; 20~30min: 30%A→30%A; 30~31min: 30%A→48%A; 31~40min: 48%A→48%A.
5. The method for separating and determining impurities related to the bemisutol timolol eye drops according to claim 1, characterized in that: The content of timolol in the test solution is 1 mg / ml; the content of timolol in the control solution is 2 μg / ml.
6. The method for separating and determining impurities related to bemisol timolol eye drops according to claim 1, characterized in that: The pH value of the sodium octane sulfonate buffer solution is 2.8-3.
2.
7. The method for separating and determining impurities related to Bimeisu Timolol Eye Drops according to claim 1, characterized in that: The pH value of the sodium octane sulfonate buffer is 3.
0.
8. The method for separating and determining impurities related to Bimeisu Timolol Eye Drops according to claim 1, characterized in that: The concentration of sodium octane sulfonate in the sodium octane sulfonate buffer is 4.3-4.34 g / L.
9. The method for separating and determining impurities related to Bimeisu Timolol Eye Drops according to claim 1, characterized in that: The filler particles of the octadecylsilane bonded silica gel have a particle size of 2-5 μm; the column temperature of the chromatographic column used in the HPLC is 33-37°C.
10. The method for separating and determining impurities related to Bimeisu Timolol Eye Drops according to claim 1, characterized in that: The detection wavelength of the detector used in the HPLC is 295±2 nm.
Citation Information
Patent Citations
Eyelid treatment
CN103841968A
Method for determining related substances in carteolol hydrochloride and eye drops thereof by ultra-high performance liquid chromatography
CN114235998A
Method for determining impurities in timolol maleate
CN114354818A
